MX9207349A - Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides. - Google Patents

Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides.

Info

Publication number
MX9207349A
MX9207349A MX9207349A MX9207349A MX9207349A MX 9207349 A MX9207349 A MX 9207349A MX 9207349 A MX9207349 A MX 9207349A MX 9207349 A MX9207349 A MX 9207349A MX 9207349 A MX9207349 A MX 9207349A
Authority
MX
Mexico
Prior art keywords
osteoporosis
parathyroid hormone
bisphosphonates
methods
treatment
Prior art date
Application number
MX9207349A
Other languages
English (en)
Inventor
Ann Dunbar Geddes
Rogely Waite Boyce
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of MX9207349A publication Critical patent/MX9207349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee métodos para mejorar la masa ósea en un ser humano u otro animal que padece de osteoporosis, que comprende un período de tratamiento de 30 días, compuesto de un régimen de administración de hormona de paratiroides y un régimen de administración de bisfosfonato.
MX9207349A 1991-12-17 1992-12-17 Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides. MX9207349A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17

Publications (1)

Publication Number Publication Date
MX9207349A true MX9207349A (es) 1993-12-01

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9207349A MX9207349A (es) 1991-12-17 1992-12-17 Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides.

Country Status (18)

Country Link
US (1) US5616560A (es)
EP (1) EP0618805A1 (es)
JP (1) JPH07502507A (es)
AU (2) AU3322593A (es)
BR (1) BR9206941A (es)
CA (1) CA2124792C (es)
CZ (1) CZ282889B6 (es)
FI (1) FI942884A (es)
HU (1) HUT68010A (es)
IL (1) IL104108A (es)
MA (1) MA23079A1 (es)
MX (1) MX9207349A (es)
NO (1) NO942241D0 (es)
NZ (1) NZ246456A (es)
RU (2) RU2112515C1 (es)
SK (1) SK74594A3 (es)
WO (1) WO1993011786A1 (es)
ZA (1) ZA929758B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
JPH08502287A (ja) * 1992-10-09 1996-03-12 ジ・アップジョン・カンパニー 抗炎症剤としてのピリミジンビスホスホン酸エステルおよび（アルコキシメチルホスフィニル）アルキルホスホン酸
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
CN1157565A (zh) * 1994-09-09 1997-08-20 普罗克特和甘保尔公司 用骨活性膦酸盐和甲状旁腺激素治疗骨质疏松症的方法
JPH10505091A (ja) * 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
ES2262145T3 (es) * 1994-12-28 2006-11-16 Gador S.A. Composicion anabolica para la masa osea que comprende olpadronato.
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
EP1123401A1 (en) * 1998-10-22 2001-08-16 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
ATE304856T1 (de) 2000-06-20 2005-10-15 Novartis Pharma Gmbh Methode zur verabreichung von biphosphonaten
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
CA2454275C (en) 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
HUP0401441A3 (en) * 2001-08-17 2012-09-28 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ES2532393T3 (es) 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
WO2004093902A1 (en) * 2003-03-19 2004-11-04 The General Hospital Corporation CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
DE602004016995D1 (de) * 2003-06-26 2008-11-20 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES
CA2534577A1 (en) * 2003-08-06 2005-02-24 Rhodia, Inc. Method for promoting bone growth
WO2005018640A1 (en) * 2003-08-20 2005-03-03 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
KR20120125601A (ko) * 2007-05-24 2012-11-16 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
KR101661730B1 (ko) 2007-08-01 2016-10-04 더 제너럴 하스피탈 코포레이션 Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
EP3875105A4 (en) * 2018-10-29 2022-06-29 Asahi Kasei Pharma Corporation Method for preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
CA3101326C (en) 2018-10-29 2023-08-01 Asahi Kasei Pharma Corporation Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone

Also Published As

Publication number Publication date
EP0618805A1 (en) 1994-10-12
ZA929758B (en) 1993-09-10
WO1993011786A1 (en) 1993-06-24
SK74594A3 (en) 1995-01-12
US5616560A (en) 1997-04-01
AU3322593A (en) 1993-07-19
NO942241D0 (no) 1994-06-15
CZ282889B6 (cs) 1997-11-12
IL104108A0 (en) 1993-05-13
FI942884A0 (fi) 1994-06-16
MA23079A1 (fr) 1993-07-01
FI942884A (fi) 1994-06-16
RU2104699C1 (ru) 1998-02-20
CA2124792C (en) 2000-07-04
HU9401798D0 (en) 1994-09-28
CA2124792A1 (en) 1993-06-24
BR9206941A (pt) 1995-05-02
RU2112515C1 (ru) 1998-06-10
AU663348B2 (en) 1995-10-05
NO942241L (es) 1994-08-09
NZ246456A (en) 1997-03-24
AU3022692A (en) 1993-06-24
CZ147794A3 (en) 1994-12-15
HUT68010A (en) 1995-05-29
RU94031209A (ru) 1996-07-27
JPH07502507A (ja) 1995-03-16
IL104108A (en) 1999-09-22

Similar Documents

Publication Publication Date Title
MX9207349A (es) Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides.
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
BR9711829A (pt) Implante cirúrgico contendo um marcador radiopaco ressorvìvel.
ES2136624T3 (es) Implante biocompatible para regular la ovulacion en yeguas.
GR3030076T3 (en) Compositions for the treatment of arthritis containing phosphonates and nsaids.
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
YU49170B (sh) Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena
AU5567790A (en) Device for reinforcing and sustaining the cap of the rotators of a human shoulder joint
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
DK0494972T3 (da) Brusedosisform samt fremgangsmåde til administration heraf
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
DK0480934T3 (da) Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt
EP0289314A3 (en) Use of igf-ii in the treatment of bone disorders
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
PL309693A1 (en) Combined osteoporosis inhibiting treatment
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
DK1001802T3 (da) Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
IT1222395B (it) Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
ATE194775T1 (de) Calcitonin enthaltende pharmazeutische zusammensetzungen
MX9704105A (es) Conjunto para uso en un ciclo terapeutico de tratamiento de la osteoporosis.
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
AR001226A1 (es) Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea